A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
NCT ID: NCT01228058
Last Updated: 2012-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1450 participants
OBSERVATIONAL
2010-11-30
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
TEG has been proposed as a superior tool to rapidly diagnose and help guide resuscitation with blood products and preclinical data suggest that TEG is both more sensitive and specific than PT or PTT for coagulation abnormalities. Based on the preclinical work led by Dr. Holcomb, our hypothesis is that the Rapid TEG will help to identify these coagulopathic patients earlier, allow for rapid MT protocol activation, and assist in developing data driven blood product transfusion guidelines.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. the coagulopathy of these patients may be detected more rapidly with RapidTEG than with traditional coagulation testing (prothrombin time, PT; international normalized ratio, INR; activated partial thromboplastin time, aPTT).
2. the disturbances in the different RapidTEG parameters will correlate with early blood product utilization.
3. the RapidTEG parameters will correlate closely with patient outcomes.
4. the Rapid TEG will be able to describe the changes that occur with coagulation over time and do so for patients with different injury mechanisms and severities
This group has recently completed enrollment on the PRospective, Observational, Multi-center Massive Transfusion sTudy (PROMMTT) to evaluate the process, the decision-making, and outcomes associated with MT. This trial is supported by a ten million dollar grant from the U.S. Department of Defense for the Center for Translational Injury Research (CeTIR) and it investigators to conduct a multi-site observational study of severely injured trauma patients who require blood transfusions. Through our efforts, we hope to determine the best method of identifying patients who will benefit from receiving different ratios of red blood cells to plasma to platelets. This study was also designed to evaluate existing MT protocols at ten leading trauma centers and to identify which protocols are associated with better survival. Results of this study will be used to develop a future randomized clinical trial that will test these protocols.
Building on the authors proven experience with (1) predictive scoring methods to predict massive transfusion, (2) creation and maturation of a massive transfusion protocol, and (3) design of large, multi-institutional studies, the PROMMTT investigators will conduct a prospective cohort study of severely injured patients (major trauma activations) arriving to three ACS-verified academic Level 1 Trauma Centers, in which the following 3 aims will be addressed:
1. To determine the prevalence and severity of immediate disturbances in coagulation by both RapidTEG and conventional coagulation parameters among major trauma activations.
2. To determine if there are specific abnormalities of RapidTEG that correlate with specific early blood product utilization.
3. To determine if RapidTEG abnormalities, when compared to kaolin-activated TEG, PT, INR and aPTT, correlate with patient outcomes in severely injured patients.
4. To determine the temporal relationship between RapidTEG parameters and anatomic injury, mechanism of injury, and severity of injury.
TEG has been proposed as a superior tool to rapidly diagnose and help guide resuscitation with blood products and preclinical data suggest that TEG is both more sensitive and specific than PT or PTT for coagulation abnormalities. Based on the preclinical work led by Dr Holcomb, we feel that the Rapid TEG will help to identify these coagulopathic patients earlier, allow for rapid MT protocol activation, and assist in developing data driven blood product transfusion guidelines. While the TEG machine is not new, widespread and thoughtful implementation in the trauma arena has not occurred. There are no transfusion algorithms constructed on large numbers of patients, admission TEG and PT/PTT values, transfusion amounts and patient outcomes. We feel that a logical step-by-step program that first constructs a data driven algorithm, and then validates the algorithm is the safest pathway to follow.
We plan to perform RapidTEG upon admission, at 3-hours post-admission, 6-hours post-admission, 12-hours post-admission, 24-hours post-admission, and then daily for 4 additional days. Blood samples (2 mL non-citrated fresh whole blood) will be obtained in addition to standard blood samples for major trauma patients. RapidTEG will be performed using the Thrombelastograph 5000 (Hemoscope Corporation, Niles, IL). Coagulation will be activated by tissue factor. Standard parameters will be obtained using Hemoscope software: TEG-ACT, r-time, K-time, alpha angle, maximum amplitude (mA), and LY30. In addition to RapidTEG, we plan to perform conventional kaolin-activated TEG, prothrombin time (PT), international normalized ratio (INR), activated thromboplastin time (aPTT), and platelet count using standard methods. The time from obtaining the blood sample until the time that the results are made available will also be recorded for all parameters tested. For the RapidTEG, this will include the final results for the test as well as the times that the TEG-ACT, alpha angle, and MA become available by graphical display.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adult trauma patients
Patients admitted to the emergency department (ED) as the highest level of acuity following a traumatic injury at three Level 1 trauma centers in the United States (UT Houston, UC San Francisco, Oregon Health Center).
RapidTEG test
The RapidTEG test will be done at the study time points (3, 6, 12, 24 hours and 4 addiitonal days).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RapidTEG test
The RapidTEG test will be done at the study time points (3, 6, 12, 24 hours and 4 addiitonal days).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Estimated age of 18 or higher
Exclusion Criteria
* CPR pre-hospital
* Prisoners - defined as anyone directly admitted from a correctional facility
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Haemonetics Corporation
INDUSTRY
The University of Texas Health Science Center, Houston
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bryan Cotton
Visiting Associate Professor - Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bryan Cotton, MD
Role: PRINCIPAL_INVESTIGATOR
The University of Texas Health Science Center, Houston
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California - San Francisco
San Francisco, California, United States
Oregon Health and Science University
Portland, Oregon, United States
Memorial Hermann Hospital - Texas Medical Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Acosta JA, Yang JC, Winchell RJ, Simons RK, Fortlage DA, Hollingsworth-Fridlund P, Hoyt DB. Lethal injuries and time to death in a level I trauma center. J Am Coll Surg. 1998 May;186(5):528-33. doi: 10.1016/s1072-7515(98)00082-9.
Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003 Jun;54(6):1127-30. doi: 10.1097/01.TA.0000069184.82147.06.
Cotton BA, Gunter OL, Isbell J, Au BK, Robertson AM, Morris JA Jr, St Jacques P, Young PP. Damage control hematology: the impact of a trauma exsanguination protocol on survival and blood product utilization. J Trauma. 2008 May;64(5):1177-82; discussion 1182-3. doi: 10.1097/TA.0b013e31816c5c80.
Niles SE, McLaughlin DF, Perkins JG, Wade CE, Li Y, Spinella PC, Holcomb JB. Increased mortality associated with the early coagulopathy of trauma in combat casualties. J Trauma. 2008 Jun;64(6):1459-63; discussion 1463-5. doi: 10.1097/TA.0b013e318174e8bc.
MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma. 2003 Jul;55(1):39-44. doi: 10.1097/01.TA.0000075338.21177.EF.
Cotton BA, Au BK, Nunez TC, Gunter OL, Robertson AM, Young PP. Predefined massive transfusion protocols are associated with a reduction in organ failure and postinjury complications. J Trauma. 2009 Jan;66(1):41-8; discussion 48-9. doi: 10.1097/TA.0b013e31819313bb.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSC-MS-10-0160
Identifier Type: -
Identifier Source: org_study_id